NCT06408220 Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer
| NCT ID | NCT06408220 |
| Status | Recruiting |
| Phase | — |
| Sponsor | City of Hope Medical Center |
| Condition | Gastric Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2024-06-27 |
| Primary Completion | 2029-10-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 240 participants in total. It began in 2024-06-27 with a primary completion date of 2029-10-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial evaluates the usefulness of various risk assessment tests, including Helicobacter pylori (H. pylori) breath testing, questionnaires, and endoscopies for identifying participants at high risk for stomach cancer. H. pylori is a bacteria that causes stomach inflammation and ulcers in the stomach. People with H. pylori infections may be more likely to develop cancer in the stomach. H. pylori breath testing can help identify the presence of H. pylori infection in a participant and help identify if the participant may be at a higher risk of developing stomach cancer. An endoscopy uses a thin, flexible lighted tube that is inserted inside the esophagus, stomach, and first part of the small intestine. This allows the doctor to see and look for abnormal areas that may need to be biopsied. Risk assessment including H. pylori evaluation, questionnaires, and endoscopies may help identify participants at high risk for stomach cancer and may be a useful screening tool for earlier stomach cancer diagnosis.
Eligibility Criteria
Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Assent, when appropriate, will be obtained per institutional guidelines * Age: ≥ 40 years to ≤ 80 years * Identify as a racial minority either Asian, Hispanic, or Black American * Willingness to: * Provide blood samples and undergo upper endoscopy Exclusion Criteria: * Identify as Non-Hispanic White * History of gastric cancer * Known premalignant lesions of the stomach * History of upper endoscopy within 2 years * Women of childbearing potential: Pregnant/ nursing * An employee who is under the direct/indirect supervision of the principal investigator (PI)/a coinvestigator/the study manager * A direct study team member
Contact & Investigator
Yanghee Woo
PRINCIPAL INVESTIGATOR
City of Hope Medical Center
Frequently Asked Questions
Who can join the NCT06408220 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 80 Years, studying Gastric Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06408220 currently recruiting?
Yes, NCT06408220 is actively recruiting participants. Visit ClinicalTrials.gov or contact City of Hope Medical Center to inquire about joining.
Where is the NCT06408220 trial being conducted?
This trial is being conducted at Duarte, United States.
Who is sponsoring the NCT06408220 clinical trial?
NCT06408220 is sponsored by City of Hope Medical Center. The principal investigator is Yanghee Woo at City of Hope Medical Center. The trial plans to enroll 240 participants.